Insufficient information provided. The PubMed abstracts supplied do not contain relevant data about CEL (carboxyl ester lipase) gene function. The abstracts discuss clinical trials for CAR-T cell therapies (exagamglogene autotemcel, lisocabtagene maraleucel, satricabtagene autoleucel), anti-inflammatory compound celastrol, hypereosinophilic syndrome variants, and sepsis treatment—none of which address CEL enzyme biology, lipid hydrolysis, or intestinal lipid absorption. To provide an accurate summary grounded in the provided sources, abstracts specifically discussing CEL's catalytic mechanisms, substrate specificity, or disease associations (particularly maturity-onset diabetes of the young 8) would be required. The UniProt functional annotations describing CEL's hydrolysis of cholesteryl esters, phospholipids, and fatty acid esters, along with its role in dietary lipid digestion and fat-soluble vitamin absorption, cannot be cited to the provided abstracts.